Table 1.
Clinical characteristics of all subjects.
Fig 1.
Serum levels of five biomarkers in control, non-NASH, NASH and other disease groups.
Levels of CK-18-M30, FGF-21, IL-1Ra and PEDF were significantly higher in NAFLD training group (A-D) whereas OPG was significantly lower (E), significant at **P < 0.01. There were no statistically significant differences among the serum biomarker levels between healthy controls and AFLD, HBV and HCV groups.
Table 2.
AUROC and OR analysis of serum biomarkers to determine effectiveness in diagnosing NASH.
Table 3.
Stepwise combination of serum biomarkers increased diagnosis performance for NASH in NAFLD patients.
Fig 2.
NASH diagnosis by serum biomarkers in NAFLD training group and validation group.
(A) NASH diagnosis solely by CK-18-M30. (B) 5-step combination of serum biomarkers in diagnosing NASH in training group. (C) 5-step combination of serum biomarkers in diagnosing NASH in validation group.